V.K Singh

COO

The global pharmaceutical CDMO market accounted for USD 184.9 billion in 2024 and is expected to reach around USD 345.6 billion by 2033 according to Precedence Research. The sector is experiencing a wave of developments in terms of technological innovations and research on the creation of new molecules. Advanced tech systems are being implemented to encircle the drug development process from the ideation stage to bulk manufacturing. Stringent regulatory standards and validations that come in several phases are making CDMOs in this sector adopt the latest technologies to expedite the various processes of the innovation ecosystem.

However, when it comes to availing products and services from CDMOs, clients face a few challenges. Precision is of high value when it comes to new APIs and pharmaceutical intermediates because the slightest imbalance can lead to contraindicated outcomes. MNC Clients choose a CDMO that never fails to deliver commitment, quality consistency, and supply chain reliability.

Blue Jet Healthcare has emerged as a one-stop CDMO for the development and manufacturing of pharmaceutical intermediates and APIs with absolute precision using the most advanced technologies and unparalleled domain expertise. The company is primarily involved in CDMO Services for several blue-chip MNCs across the world and developing intermediates and APIs for medications related to cardiovascular oncology, CNS, urinary, and a few others. The MedTech arm of the company focuses on developing performance chemicals that will be able to provide further precision to diagnostic procedures. “There are numerous innovations taking place in the segments that we are working on. We aim to provide innovative treatments for complex diseases and add value to preventive and diagnostic healthcare across the world”, mentioned V.K Singh, COO, of Blue Jet Healthcare.

Operational Excellence

Be it technology or product R&D, the company is always a step ahead of its competitors. Firstly, its success depends on the width and depth of services combined with quality. It has the latest CAD and analytics machinery and equipment to expedite the processes of drug manufacturing. Blue Jet Healthcare partners right from the proof of concept (pre-clinical) stage to validation phases and commercialization. It provides expertise at ideation and optimization stages as well. “APIs and pharmaceutical intermediates have three phases of validation. We provide samples to our clients for all the validations until we start providing them with bulk quantities. Our company offers a holistic bench to bulk solution for client organizations and acts as a pure play CDMO”, stated the COO.

When it comes to Medtech, the company is involved in the segment of imaging for diagnostic procedures. The chemicals that are developed by it help in better imaging for procedures like MRI and likewise. It produces some of the best kinds of chemicals currently available in the industry. According to the COO, the company’s contribution to this segment has helped in giving a boost to the preventive care of patients. Precision in imaging means better diagnostics

can be carried out which in turn provides clarity to the treatment processes and gives better outcomes. The chemicals that we manufacture support a diagnostic procedure every three seconds”, he said.

Blue Jet Healthcare was started more than five decades ago with a nitration platform and today, it provides complete CDMO services to many countries worldwide with three manufacturing facilities in India. Having been operational in the industry for more than five decades, Blue Jet has developed its state-of-the-art nitration and hydrogenation platforms. With time, the company has forayed into other verticals and developed its iodination platform and also a cryogenic platform. It is in the process of developing some enzymatic products as well. Last year, the company started a separate arm for manufacturing pharmaceutical intermediates and basic building blocks for peptides.

As mentioned earlier, the company aims to develop treatments for complex diseases, and to achieve that, it puts in considerable effort into R&D. There are two R&D units that the company currently has. The first unit is dedicated to process excellence and research, keeping in mind the changing trends and technologies of the industries. The second R&D department is focused on developing new molecules that can benefit the company and also add value to client products. “We are currently providing quite a few complex molecules for chronic treatments, where end products are still under patent. We have also developed an advanced intermediate for an NCE for MRI”, stated VK.

The company also develops and manufactures high-intensity sweeteners for the pharmaceutical and FMCG industry. They are used for various purposes like sweetening toothpaste, and flavoring colas, and Blue Jet Healthcare is one of the trusted manufacturers of this product. In this regard, it is worth mentioning that the quality of these sweeteners highly affects brand value in the market. Currently, the R&D department is highly focused on making the quality of the sweeteners better and also making it cost-effective. “We are looking at various forward integration opportunities and trying to come up with new kinds of sweeteners in the coming years”, added the COO.

Aggressive Growth Plans

Having been operational for more than five decades now, the company has gained considerable trust and recognition in the global market and conducts more than 90 percent of business outside India. It has a solar plant facility that provides the company with up to 75 percent of its energy requirement. The COO informed us about a few forward integration and NCE opportunities that are lined up for them in the coming years. When it comes to PI and API manufacturing, it is currently manufacturing the building blocks for peptides and several products in the chronic therapy space and looking at continuing with the good work. The company wants to move ahead based on two aspects which are capacity to deliver and R&D prowess. “Looking ahead, we are expanding the company operations based on our R&D prowess and usage of the latest technologies. In the coming year, we plan on increasing our R&D strength by 40-50 percent and also in the process of an additional R&D plant. We want to excel in this field based on our chemistry expertise, atom efficiency, and reaction kinetics”. The company has started monitoring the carbon footprint from cradle to grave, concluded the COO.